Fusion Biopsy Market, By Biopsy Route (Transrectal and Transperineal), By Product (Equipment (MRI machines, Ultrasound devices, Fusion biopsy systems, and Others) and Consumables (Biopsy needles, Imaging contrast agents, and Others)), By Application (Pros

Fusion biopsy combines two medical imaging technologies, magnetic resonance imaging (MRI), and ultrasound, to provide real-time image guidance for biopsy procedures with improved accuracy. It helps physicians locate suspicious tissue in the body and obtain tissue samples with minimal risk of sampling error or missing lesions. With rising cases of prostate, lung, and breast cancer worldwide, the demand for advanced biopsy techniques like fusion biopsy is increasing globally. Factors such as growing geriatric population, increasing awareness about early cancer diagnosis, technological advancements in medical imaging systems, and rising healthcare expenditure in developing countries are expected to drive the market growth during the forecast period.

Market Dynamics:

The global fusion biopsy market is driven by the rising prevalence of cancer, increasing preference for minimally invasive surgeries, and growing need for accurate tissue sampling techniques. According to WHO, cancer burden is expected to rise by over 70% in the next 20 years worldwide. Fusion biopsy aids in detecting cancers at an early stage with minimal chances of sampling errors. This is propelling its adoption globally. However, high installation and maintenance costs of fusion biopsy devices is restraining market growth. Opportunities for market players lie in expanding their regional presence in emerging markets, launching affordable devices and offering pay-per-use business models. Increasing approvals and launch of advanced devices integrated with artificial intelligence, robotics and 3D imaging technologies will also offer new opportunities in coming years. For example, in 2022, CMR Surgical, a medical equipment manufacturer, received breakthrough device designation from the U.S. FDA for its Versius surgical robotic system for soft tissue procedures.

Key Features of the Study:

• This report provides in-depth analysis of the global fusion biopsy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global fusion biopsy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GE Healthcare, Koninklijke Philips N.V., FUJIFILM Corporation, Siemens Healthineers, Hitachi, Ltd., Canon Medical Systems Corporation, Medtronic, Hologic, Inc., Varian Medical Systems, Boston Scientific Corporation, Becton, Dickinson and Company, Agilent Technologies, Inc., 3M Company, Carestream Health, and Neusoft Medical Systems Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global fusion biopsy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fusion biopsy market

• Biopsy Route Insights (Revenue, USD Mn, 2020 - 2032)
• Transrectal
• Transperineal
• Product Insights (Revenue, USD Mn, 2020 - 2032)
• Equipment
• MRI machines
• Ultrasound devices
• Fusion biopsy systems
• Others
• Consumables
• Biopsy needles
• Imaging contrast agents
• Others
• Application Insights (Revenue, USD Mn, 2020 - 2032)
• Prostate Cancer
• Others
• End User Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals
• Diagnostic Centers
• Ambulatory Care Centers
• Academic & Research Laboratories
• Others
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• GE Healthcare
• Koninklijke Philips N.V.
• FUJIFILM Corporation
• Siemens Healthineers
• Hitachi, Ltd.
• Canon Medical Systems Corporation
• Medtronic
• Hologic, Inc.
• Varian Medical Systems
• Boston Scientific Corporation
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• 3M Company
• Carestream Health
• Neusoft Medical Systems Co., Ltd.